Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms

Fig. 5

Bevacizumab and regorafenib do not appear to impact ONC201’s key mechanisms of cell death. a Serum TRAIL for TRAIL ELISA taken at week 3 in HCT116 xenograft-bearing athymic nude mice. N = 5. CHOP and DR5 protein in (b) HT29 and (c) HCT116 cells from live cell imaging using CHOP-800, DR5–800, and Actin-700 on LiCor Odyssey. Cells treated for 48 h. ONC201 dose was 5 μM. Bevacizumab dose was 1 mg/ml

Back to article page